CN102335249A - Oral capsule for treating II-type diabetes - Google Patents
Oral capsule for treating II-type diabetes Download PDFInfo
- Publication number
- CN102335249A CN102335249A CN2011103009875A CN201110300987A CN102335249A CN 102335249 A CN102335249 A CN 102335249A CN 2011103009875 A CN2011103009875 A CN 2011103009875A CN 201110300987 A CN201110300987 A CN 201110300987A CN 102335249 A CN102335249 A CN 102335249A
- Authority
- CN
- China
- Prior art keywords
- parts
- capsule
- diabetes
- extractum
- capsules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses an oral capsule for treating II-type diabetes. The oral capsule is prepared by the method comprising the following steps: (1) respectively weighing the following components in parts by weight: 30+/-3 parts of raw astragalus mongholicus, 30+/-3 parts of glossy privet fruit, 30+/-3 parts of poria, 9+/-1 parts of American ginseng, 15+/-2 parts of medical dogwood, 15+/-2 parts of kudzuvine root, 15+/-2 parts of chicken's gizzard-membrane, 30+/-2 parts of red-rooted salvia root, 15+/-2 parts of snakegourd fruit, and 9+/-1 parts of golden thread, mixing and sufficiently infiltrating with an infiltration amount of ethanol; (2) heating, refluxing and extracting to obtain an extract; (3) mixing with starch or dextrin by using the prepared extract as an adhesive to prepare a soft material, and screening the soft material through a 20-mesh screen to prepare capsule medicinal filling particles; and (4) selecting 00# capsules, and filling the capsules with the capsule medicinal filling particles to obtain the oral capsules for treating the II-type diabetes. Pharmacological tests prove that the effect of the capsules for treating the II-type diabetes is better than that of a positive control group, and the capsules have important clinical application value.
Description
Technical field
The present invention relates to a kind of capsule of treating diabetes, relate in particular to a kind of oral capsule of treating type ii diabetes.
Background technology
Along with living standards of the people improve, factor affecting such as the change of dietary structure, life style conversion and gene, the sickness rate of diabetes increases day by day.China has about more than 4,000 ten thousand people of diabetics now according to incompletely statistics; And also increase progressively with more than 100 ten thousand people's onset speed every year; Wherein suffer from non-insulin-depending type and be that the type ii diabetes patient accounts for the diabetes total number of persons about 90%, human existence and health in serious threat.Lasting hyperglycemia can cause the complication of cardiac muscle, blood vessel, nervous system, kidney etc.Therefore, blood sugar control raises becomes the primary and foremost purpose of treatment diabetes.At present; The therapeutic scheme of type ii diabetes mainly is oral hypoglycemic (oral hypoglycemic drugs and a prolonged application insulin (insulin); But there is side reaction in various degree; And be prone to lose efficacy or took inconvenience, so the searching blood sugar reducing function is lasting and Chinese Traditional Medicines that toxicity is little become the research focus.
Summary of the invention
To clinical demand, the purpose of this invention is to provide the oral capsule of the treatment type ii diabetes that a kind of blood sugar reducing function is lasting and toxicity is little.
The oral capsule of treatment type ii diabetes of the present invention is made by following method:
(1) in weight portion; Take by weighing 30 ± 3 parts of Radix Astragali, 30 ± 3 parts of Fructus Ligustri Lucidi, 30 ± 3 parts in Poria, 9 ± 1 parts of Radix Panacis Quinquefoliis, 15 ± 2 parts of Fructus Corni, 15 ± 2 parts of Radix Puerariaes, 15 ± 2 parts of Endothelium Corneum Gigeriae Galli, 30 ± 2 parts of Radix Salviae Miltiorrhizaes, 15 ± 2 parts of Fructus Trichosanthis, 9 ± 1 parts of Rhizoma Coptidis respectively, mixing then and using the volume ratio of submergence amount is that 70%～80% ethanol fully soaked into 24-36 hour;
(2) under 60～70 ℃ of temperature, the heating and refluxing extraction extractum repeats twice, and each 1～4 hour, merge extracted twice liquid, filter, it is 1.2～1.3 (70 ℃) that decompression recycling ethanol, extractum are concentrated into relative density; Add the water of its 3～4 times of volumes then, stir, left standstill 20-40 hour at 0～4 ℃, getting supernatant, to be evaporated to relative density be 1.30 ± 0.1 (70 ℃), obtains extract extractum;
(3) with the extractum that makes as binding agent and starch or the mixed soft material of dextrin, then soft material is crossed 20 mesh sieves and makes wet granular, wet granular is put 60～70 ℃ of down oven dry, dried granule promptly gets the pharmaceutical capsules filler particles with 20 mesh sieve granulate;
(4) choose capsule No. 00, earlier capsule medicated cap, capsule status are opened, the capsule body inserts in the capsule board hole, regulates the levels distance; Make the capsule mouth equal, then the capsule filler particles is laid on the plate face, vibrate capsule board gently, make particles filled even with the plate face; After filling up each capsule, with the unnecessary pharmaceutical capsules filler particles cleaning of plate face, jack-up capsule body; Fit capsule medicated cap takes out capsule, promptly gets the oral capsule of treating type ii diabetes.
The oral capsule of above-mentioned treatment type ii diabetes is preferably made by following method:
(1) in weight portion; Take by weighing 30 parts of Radix Astragali, 30 parts of Fructus Ligustri Lucidi, 30 parts in Poria, 9 parts of Radix Panacis Quinquefoliis, 15 parts of Fructus Corni, 15 parts of Radix Puerariaes, 15 parts of Endothelium Corneum Gigeriae Galli, 30 parts of Radix Salviae Miltiorrhizaes, 15 parts of Fructus Trichosanthis, 9 parts of Rhizoma Coptidis respectively, mixing then and using the volume ratio of submergence amount is that 75% ethanol fully soaked into 30 hours;
(2) under 60 ℃ of temperature, the heating and refluxing extraction extractum repeats twice, and each 2 hours, merge extracted twice liquid, filter, it is 1.2～1.3 (70 ℃) that decompression recycling ethanol, extractum are concentrated into relative density; Add the water of its 3 times of volumes then, stir, left standstill 24 hours at 1～4 ℃, getting supernatant, to be evaporated to relative density be 1.30 ± 0.1 (70 ℃), obtains extract extractum;
(3) with the extractum that makes as binding agent and starch or the mixed soft material of dextrin, then soft material is crossed 20 mesh sieves and makes wet granular, wet granular is put 65 ℃ of down oven dry, dried granule promptly gets the pharmaceutical capsules filler particles with 20 mesh sieve granulate;
(4) choose capsule No. 00, earlier capsule medicated cap, capsule status are opened, the capsule body inserts in the capsule board hole, regulates the levels distance; Make the capsule mouth equal, then the pharmaceutical capsules filler particles is laid on the plate face, vibrate capsule board gently, make particles filled even with the plate face; After filling up each capsule, with the unnecessary pharmaceutical capsules filler particles cleaning of plate face, jack-up capsule body; Fit capsule medicated cap takes out capsule, promptly gets the oral capsule of treating type ii diabetes.
The type ii diabetes traditional Chinese medical science belongs to the diabetes category, and diabetes is many because of intense heat of YANG MING, the bright body fluid that disappears, and the damage lung stomach then consumes impairment of QI Tianjin for a long time, and it is more thirsty more to disappear.There is viewpoint to think deficiency of spleen and stomach now, deficiency of QI in middle-JIAO, it is to cause this sick main cause that gas Tianjin consumption is hindered, so most of diabetics has weakness of the spleen and stomach to show except that the resembling of deficiency of the kidney yin arranged more, demonstrate,proves shape like weak, hyperhidrosis, loose stool etc.What the oral capsule prescription of treatment type ii diabetes according to the invention was controlled quenches one's thirst, and belongs to not cloth Tianjin of gas, deficiency of spleen and stomach, stomach Tianjin deficiency person.Reuse Radix Astragali among the we, sweet in the mouth, slightly warm in nature is returned the taste warp, is the key medicine of invigorating the spleen and replenishing QI, Shennong's Herbal meaning its main " tonify deficiency ", " book on Chinese herbal medicine converges and says " more sayed it is " medicine of tonifying the lung spleen invigorating ".For insufficiency of the spleen can not cloth Tianjin quench one's thirst, Radix Astragali can tonifying QI to produce body fluid, promotes generation and the defeated cloth of body fluid and the effect of quenching the thirst is arranged; Fructus Ligustri Lucidi, sweet-bitter flavor is cool in nature, returns the Liver and kidney warp, and the merit of nourishing the liver and kidney is arranged, and essentials of Matea Medica carries it can " liver and kidney tonifying, settling five organs, strong waist knee joint ".Two medicine compatibilities, enriching spleen-QI, nourishing kidney-yin, invigorating both QI and YIN is monarch drug altogether.Poria, sweet in the mouth and light, Gan Zeneng mends, and lightly then can ooze; But the power of Radix Astragali tonify deficiency is strengthened in both spleen invigorating invigorating middle warmer, but promoting diuresis to eliminate damp pathogen again, and making does not wetly have institute and gathers; The expectorant life of having no way of, eliminating evil and do not hinder healthy energy, the Shennong's Herbal cloud its can " the contrary gas of the main breast side of body ... cold and heat; stuffy sensation with restlessness, cough with dyspnea, mouthful burnt dry tongue, diuresis "; Radix Panacis Quinquefolii, sweet little bitter cool, kind boosting qi and nourishing yin, clearing away heat and promoting production of body fluid, " Bencao Congxin " are called its " relieving restlessness is tired for tonifying the lung pathogenic fire reducing, born fluid, empty and have the fiery person suitable ", with the Radix Astragali, Poria compatibility, can assist strengthening the spleen gas; With the same usefulness of Fructus Ligustri Lucidi, can strengthen the effect of YIN nourishing and the production of body fluid promoting again; Fructus Corni, sour and astringent tepor can liver and kidney tonifying, again can the controlling nocturnal emission with astringent drugs reducing urination, the merit of tool envelope Tibetans again among tonification, say as " property of medicine opinion ": Fructus Corni can " the kidney invigorating gas, emerging vagina add marrow, treat tinnitus ... only the old man urinates and does not save." Materia Medica of Decoction also calls: " and sliding then QI prostration, so astringent is received it, Fructus Corni ends normal urination, secret vital essence is got its sour-puckery flavor to receive cunning." last three medicine compatibilities, both can assist the monarch drug supplementing QI and nourishing YIN, but clearing heat and expelling damp again, it is astringent or styptic treatment for spontaneous sweating to restrain to hold concurrently, and invigorating middle warmer has rushes down, and receipts are arranged in the profit, oppose each other and yet also complement each other, be ministerial drug altogether.Radix Puerariae, the sweet in the mouth suffering is cool in nature, returns the taste warp; Among heat clearing away, can inspire the gas of the clear sun of taste to rise again, and the merit of promoting the production of body fluid to quench thirst is arranged; Carry its " main quenching one's thirst " as Shennong's Herbal, " property of medicine opinion " also called it can " end excessive thirst ", with compatibilities such as the Radix Astragali, Radix Panacis Quinquefoliis; Supplementing QI and nourishing YIN, clearing away heat and promoting production of body fluid; Endothelium Corneum Gigeriae Galli, sweet flat, merit is arrogated to oneself invigorating the spleen and stomach, promoting digestion and removing stagnation, the controlling nocturnal emission with astringent drugs reducing urination for preventing enuresis, " Japan hanako materia medica " Yan Qike " stopping leak is smart ", the merit that " the southern regions of the Yunnan Province book on Chinese herbal medicine " called it to be had " alleviating distention in middle-JIAO spleen invigorating, the mill stomach helps digestion ", with the Radix Astragali, Poria mutually 5, be good for the stomach and in; With the Fructus Corni compatibility, add the astringent or styptic treatment for spontaneous sweating power of strong convergence; Radix Salviae Miltiorrhizae, hardship is slightly cold, and has the effect that nourishes blood among invigorating blood circulation concurrently, " Japan hanako materia medica " Yan Qizhu " broken stagnated blood, mend new hemopoietic ", " book on Chinese herbal medicine is just read " more call its " merit is with four things, can blood stasis dispelling with tissue regeneration promoting ... property is gentle and walk blood "; Fructus Trichosanthis, sweet cold and moisten, kind removing heat-phlegm, the promoting the circulation of QI dissipating depression of QI, the Compendium of Material Medica cloud its can " lung moistening be dry, pathogenic fire reducing, the clearing away phlegm knot, throat is only quenched one's thirst ", share with Poria, strengthen the effect that eliminating dampness by diuresis is eliminated the phlegm; With Radix Salviae Miltiorrhizae mutually 5, blood circulation promoting and blood stasis dispelling, expectorant powder junction, the article of tonification in the compatibility side, tonify without causing stagnation, eliminating evil just the wound; Rhizoma Coptidis, bitter cold, heat clearing and damp drying, eliminating fire and detoxication, with YIN nourishing and the production of body fluid promoting medicine compatibility, nourishing yin and purging fire, heresy is just taken into account, treating both the principal and the secondary aspects of a disease at the same time.The last five tastes are adjuvant drug altogether.Full side's compatibility is played supplementing QI and nourishing YIN altogether, the effect that promoting the production of body fluid to quench thirst, heat clearing and blood circulation promoting reduce phlegm.
In order to understand essence of the present invention better, pharmacological evaluation and the result with the oral capsule of treatment type ii diabetes according to the invention explains that it is at the remarkable result aspect the blood sugar lowering below.
Diabetes model preparation: alloxan has the effect of selective destruction β cell, and behind the intravenous injection alloxan, rat is damaged because of beta Cell of islet, forfeiture synthetic with excreting insulin ability and bring out diabetes.
Use the oral capsule high and low dose group of treatment type ii diabetes according to the invention and compare with the normal saline group, capsule according to the invention can significantly reduce the blood glucose of the diabetes rat of model induced by alloxan, C peptide and insulin level in the elevating blood.
Islet tissue pathological section microscopy finds that capsule high and low dose group according to the invention is compared with the normal saline group, and the pancreatic tissue pathological lesion is light, and islets of langerhans inner cell check figure order is significantly more than the normal saline group.
Find also that in addition capsule according to the invention can significantly reduce the blood glucose of the hyperglycemia rabbit that epinephrine brings out.
Press WHO diabetes diagnosis Standard Selection type ii diabetes patient 464 examples, be divided into treatment group and matched group at random.364 examples are organized in treatment, wherein male 197 examples, women 167 examples, 40～65 years old age, the course of disease 1～13 year; Severity extent: slight 58 examples, moderate 172 examples, severe 134 examples.Matched group 100 examples, wherein male 59 examples, women 41 examples, 40～65 years old age, the course of disease 1～12 year; Severity extent: slight 10 examples, moderate 58 examples, severe 32 examples.All keep on a diet on request for two groups.Oral embodiment 1 said capsule is organized in treatment, every 3.5g, and each 6, every day 3 times, early, middle and late 30min before the meal is oral.The oral SHENQI JIANGTANG sheet of matched group, every 3.5g, each 5, every day 3 times, early, middle and late 30min before the meal is oral.Two groups of drug treatments are 60 days.According to " the clinical research guideline of new Chinese medicine treatment diabetes (diabetes) " middle curative effect determinate standard that Ministry of Public Health is formulated, the embodiment of the invention 1 said capsule group 364 examples, produce effects 196 examples, effective 114 examples, invalid 54 examples, total effective rate 85.16%.Matched group 100 examples, produce effects 20 examples, effective 48 examples, invalid 32 examples, total effective rate 68%.Produce effects and total effective rate more all have significant difference (P＜0.01) between two groups.Prompting is to improving thirsty polydipsia, rapid digestion of food and polyorexia, polyuria, vexed, clinical total effective rate such as body is tired, weak, sweating, and capsule treatment group of the present invention is superior to matched group, and disclosing capsule according to the invention has important clinical application value.
The specific embodiment
Embodiment 1:
(1) in weight portion (unit: gram); Take by weighing 30 parts of Radix Astragali, 30 parts of Fructus Ligustri Lucidi, 30 parts in Poria, 9 parts of Radix Panacis Quinquefoliis, 15 parts of Fructus Corni, 15 parts of Radix Puerariaes, 15 parts of Endothelium Corneum Gigeriae Galli, 30 parts of Radix Salviae Miltiorrhizaes, 15 parts of Fructus Trichosanthis, 9 parts of Rhizoma Coptidis respectively, mixing then and using the volume ratio of submergence amount is that 75% ethanol fully soaked into 30 hours;
(2) under 60 ℃ of temperature, the heating and refluxing extraction extractum repeats twice, and each 2 hours, merge extracted twice liquid, filter, it is 1.2～1.3 (70 ℃) that decompression recycling ethanol, extractum are concentrated into relative density; Add the water of its 3 times of volumes then, stir, left standstill 24 hours at 1～4 ℃, getting supernatant, to be evaporated to relative density be 1.30 ± 0.1 (70 ℃), obtains extract extractum;
(3) with the extractum that makes as binding agent and starch or the mixed soft material of dextrin, then soft material is crossed 20 mesh sieves and makes wet granular, wet granular is put 65 ℃ of down oven dry, dried granule promptly gets the pharmaceutical capsules filler particles with 20 mesh sieve granulate;
(4) choose capsule No. 00, earlier capsule medicated cap, capsule status are opened, the capsule body inserts in the capsule board hole, regulates the levels distance; Make the capsule mouth equal, then the pharmaceutical capsules filler particles is laid on the plate face, vibrate capsule board gently, make particles filled even with the plate face; After filling up each capsule, with the unnecessary pharmaceutical capsules filler particles cleaning of plate face, jack-up capsule body, fit capsule medicated cap; Take out capsule, promptly get the oral capsule of treating type ii diabetes, wherein contain 3.5g medicine filler particles/capsules.
Embodiment 2:
The experimentation of embodiment 1 said capsule hypoglycemic activity
1 experiment material
1.1 animal: the Wistar rat, male, body weight 200～300g; Purebred new zealand rabbit, male, body weight 2～3kg, Shandong University's new drug assessment centers provides.
1.2 reagent: alloxan, epinephrine, glyburide, insoral, diabetes pill is available from medication purchasing supply station, Shandong; C peptide and insulin radioimmunology analysis medicine box are available from Beijing Chinese Research Institute of Atomic Energy Sciences.
1.3 instrument: blood-sugar detecting instrument and blood glucose strip (Luo Shi diagnostic companies); The automatic Y calculating instrument of four probes (Beijing permanent Order instrument and meter company limited).
2 methods and result
2.1 embodiment 1 said capsule is to the influence of blood glucose, C peptide, insulin and the pancreatic tissue of the diabetes rat of model induced by alloxan.
Get 70 of healthy male Wistar rats, body weight 200～300g.Select blood glucose normal range (10 of 3.3～5mmol/L) rats are as the normal control group, and all the other are all through tail vein injection alloxan 40mg/kg, behind the injection 48h respectively with blood-sugar detecting instrument and blood glucose strip survey blood glucose.Get 40 of the rats of range of blood sugar 7～27mmol/L, be divided into 4 groups at random by the blood glucose height.Medication group gastric infusion every day 1 time, matched group and normal control group wait the normal saline of capacity respectively, give 1mL by every 100g body weight, continuous use 70d.Respectively at behind the medicine the 20th, 40,70 day, fasting 12h surveyed blood glucose 1 time, and the result sees table 1.
Table 1 embodiment 1 said capsule is to the influence (
N=10) of a large amount of blood glucose of hyperglycemia of model induced by alloxan
Annotate: with normal saline group ratio,
*P＜0.05,
*P＜0.01.
Last is surveyed behind the blood glucose respectively from heart extracting blood 4mL, centrifugally goes out serum, puts with C peptide and insulin and exempts from medicine box and survey C peptide and insulin concentration respectively, and the result sees table 2.
Table 2 embodiment 1 said capsule is to the influence (
N=10) of model induced by alloxan hyperglycemic rat plasma C peptide and insulin level
Annotate: with normal saline group ratio,
*P＜0.05,
*P＜0.01.
Last sacrificed by decapitation rat, the taking-up pancreatic tissue of cutting open the belly is used 10% formalin fixed, FFPE, section is with H.E and Gomori aldehyde-fuchsin (G.A) dyeing, microscopy.
Acetonideexample 1 said capsule high and low dose group is compared with the normal saline group, and the pancreatic tissue infringement is light, and the pancreatic islet endocrine form is normal, structural integrity.Embodiment 1 said capsule high and low dose group navy blue cell check figure is (individual/μ m
2) be respectively 7.92 ± 0.35 and 7.75 ± 0.95, compare P＜0.01 and P＜0.05 with normal saline group 5.02 ± 1.11.
2.2 the influence of the hyperglycemia that embodiment 1 said capsule brings out epinephrine man rabbit blood glucose.
Get 36 of purebred new zealand rabbits, measure and write down the preceding blood glucose value of each rabbit medicine respectively.Get 30 of blood glucose normal rabbits, be divided into 5 groups at random.Medication group gastric infusion every day 1 time, matched group wait the normal saline (4ml/kg) of capacity, continuous use 14d.1h measures the record blood glucose value respectively behind the last medicine.Each rabbit is distinguished subcutaneous injection epinephrine 0.08mg/kg then, each rabbit 1h, 2h and 4h blood glucose value behind the mensuration injection epinephrine, and the result sees table 3.
Table 3 embodiment 1 said capsule brings out the influence (
N=6) of hyperglycemia man rabbit blood glucose to epinephrine
Annotate: with normal saline group ratio,
*P＜0.05,
*P＜0.01.
3 discuss
Experimental result shows that capsule high and low dose group according to the invention is compared with the normal saline group, can significantly reduce the blood glucose of the diabetes rat of model induced by alloxan, C peptide and insulin level in the elevating blood.
Islet tissue pathological section microscopy finds that capsule high and low dose group according to the invention is compared with the normal saline group, and the pancreatic tissue pathological lesion is light, and islets of langerhans inner cell check figure order is significantly more than the normal saline group.
Find also that in addition capsule according to the invention can significantly reduce the blood glucose of the hyperglycemia rabbit that epinephrine brings out.
Embodiment 3:
The report of embodiment 1 said capsule clinical treatment type ii diabetes
3.1 case is selected:
Case is pressed WHO diabetes diagnosis Standard Selection, is the II diabetics, and meets the dialectical standard of deficiency of both QI and YIN disease in " the clinical research guideline of new Chinese medicine treatment diabetes (diabetes) ".Accept patient's 464 examples altogether for medical treatment, be divided into treatment group and matched group at random.364 examples are organized in treatment, wherein male 197 examples, women 167 examples, 40～65 years old age, the course of disease 1～13 year; Severity extent: slight 58 examples, moderate 172 examples, severe 134 examples.Matched group 100 examples, wherein male 59 examples, women 41 examples, 40～65 years old age, the course of disease 1～12 year; Severity extent: slight 10 examples, moderate 58 examples, severe 32 examples.
3.2 Therapeutic Method:
All keep on a diet on request for two groups.Oral embodiment 1 said capsule is organized in treatment, every 3.5g, and each 6, every day 3 times, early, middle and late 30min before the meal is oral.The oral SHENQI JIANGTANG sheet of matched group, every 3.5g, each 5, every day 3 times, early, middle and late 30min before the meal is oral.Two groups of drug treatments are 60 days.
3.3 observation index
Fasting glucose and 2 hours after the meal blood glucose.
3.4 clinical development standard
With reference to curative effect determinate standard in " the clinical research guideline of new Chinese medicine treatment diabetes (diabetes) " of Ministry of Public Health formulation.
3.5 therapeutic outcome:
Embodiment 1 said capsule group 364 examples, produce effects 196 examples, effective 114 examples, invalid 54 examples, total effective rate 85.16%.Matched group 100 examples, produce effects 20 examples, effective 48 examples, invalid 32 examples, total effective rate 68%.Produce effects and total effective rate more all have significant difference (P＜0.01) between two groups.Prompting is to improving thirsty polydipsia, rapid digestion of food and polyorexia, polyuria, vexed, clinical total effective rate such as body is tired, weak, sweating, and treatment group (capsule according to the invention) is superior to matched group, and disclosing capsule according to the invention has important clinical application value.
The relatively demonstration of fasting glucose and 2 hours after the meal blood glucose before and after two groups of patient treatments, two groups of curative effects to fasting glucose and 2 hours blood glucose after the meal are all relatively good, with treat before significant difference (P＜0.01) is more all arranged, the comparison there was no significant difference is seen table 4 between group.
Before and after the treatment of table 4 liang group on an empty stomach with the comparison of 2 hours blood glucose after the meal (
MmolL
-1)
Annotate: with group ratio before and after the treatment,
*P＜0.01.
Claims (2)
1. oral capsule of treating type ii diabetes is made by following method:
(1) in weight portion; Take by weighing 30 ± 3 parts of Radix Astragali, 30 ± 3 parts of Fructus Ligustri Lucidi, 30 ± 3 parts in Poria, 9 ± 1 parts of Radix Panacis Quinquefoliis, 15 ± 2 parts of Fructus Corni, 15 ± 2 parts of Radix Puerariaes, 15 ± 2 parts of Endothelium Corneum Gigeriae Galli, 30 ± 2 parts of Radix Salviae Miltiorrhizaes, 15 ± 2 parts of Fructus Trichosanthis, 9 ± 1 parts of Rhizoma Coptidis respectively, mixing then and using the volume ratio of submergence amount is that 70%～80% ethanol fully soaked into 24-36 hour;
(2) under 60～70 ℃ of temperature, the heating and refluxing extraction extractum repeats twice, and each 1～4 hour, merge extracted twice liquid, filter, it is 1.2～1.3 (70 ℃) that decompression recycling ethanol, extractum are concentrated into relative density; Add the water of its 3～4 times of volumes then, stir, left standstill 20-40 hour at 0～4 ℃, getting supernatant, to be evaporated to relative density be 1.30 ± 0.1 (70 ℃), obtains extract extractum;
(3) with the extractum that makes as binding agent and starch or the mixed soft material of dextrin, then soft material is crossed 20 mesh sieves and makes wet granular, wet granular is put 60～70 ℃ of down oven dry, dried granule promptly gets the pharmaceutical capsules filler particles with 20 mesh sieve granulate;
(4) choose capsule No. 00, earlier capsule medicated cap, capsule status are opened, the capsule body inserts in the capsule board hole, regulates the levels distance; Make the capsule mouth equal, then the pharmaceutical capsules filler particles is laid on the plate face, vibrate capsule board gently, make particles filled even with the plate face; After filling up each capsule, with the unnecessary pharmaceutical capsules filler particles cleaning of plate face, jack-up capsule body; Fit capsule medicated cap takes out capsule, promptly gets the oral capsule of treating type ii diabetes.
2. the oral capsule of treatment type ii diabetes as claimed in claim 1 is characterized in that, is made by following method:
(1) in weight portion; Take by weighing 30 parts of Radix Astragali, 30 parts of Fructus Ligustri Lucidi, 30 parts in Poria, 9 parts of Radix Panacis Quinquefoliis, 15 parts of Fructus Corni, 15 parts of Radix Puerariaes, 15 parts of Endothelium Corneum Gigeriae Galli, 30 parts of Radix Salviae Miltiorrhizaes, 15 parts of Fructus Trichosanthis, 9 parts of Rhizoma Coptidis respectively, mixing then and using the volume ratio of submergence amount is that 75% ethanol fully soaked into 30 hours;
(2) under 60 ℃ of temperature, the heating and refluxing extraction extractum repeats twice, and each 2 hours, merge extracted twice liquid, filter, it is 1.2～1.3 (70 ℃) that decompression recycling ethanol, extractum are concentrated into relative density; Add the water of its 3 times of volumes then, stir, left standstill 24 hours at 1～4 ℃, getting supernatant, to be evaporated to relative density be 1.30 ± 0.1 (70 ℃), obtains extract extractum;
(3) with the extractum that makes as binding agent and starch or the mixed soft material of dextrin, then soft material is crossed 20 mesh sieves and makes wet granular, wet granular is put 65 ℃ of down oven dry, dried granule promptly gets the pharmaceutical capsules filler particles with 20 mesh sieve granulate;
(4) choose capsule No. 00, earlier capsule medicated cap, capsule status are opened, the capsule body inserts in the capsule board hole, regulates the levels distance; Make the capsule mouth equal, then the pharmaceutical capsules filler particles is laid on the plate face, vibrate capsule board gently, make particles filled even with the plate face; After filling up each capsule, with the unnecessary pharmaceutical capsules filler particles cleaning of plate face, jack-up capsule body; Fit capsule medicated cap takes out capsule, promptly gets the oral capsule of treating type ii diabetes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103009875A CN102335249B (en) | 2011-10-09 | 2011-10-09 | Oral capsule for treating II-type diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103009875A CN102335249B (en) | 2011-10-09 | 2011-10-09 | Oral capsule for treating II-type diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102335249A true CN102335249A (en) | 2012-02-01 |
| CN102335249B CN102335249B (en) | 2013-04-03 |
Family
ID=45511350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103009875A Expired - Fee Related CN102335249B (en) | 2011-10-09 | 2011-10-09 | Oral capsule for treating II-type diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102335249B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103202423A (en) * | 2013-04-17 | 2013-07-17 | 合肥工业大学 | Fructus trichosanthis polysaccharide composite capsule and preparation method thereof |
| CN104474193A (en) * | 2014-11-17 | 2015-04-01 | 孙静 | Coordinated application of traditional Chinese medicines in diabetes prevention acupuncture therapy |
| CN110755507A (en) * | 2019-10-31 | 2020-02-07 | 贵州省兴仁市中医院 | Formula for treating yin deficiency type diabetes and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1726967A (en) * | 2005-07-26 | 2006-02-01 | 浙江省中药研究所 | Chinese materia medica preparation for treating diabetic nephropathy, and preparation method |
| CN101024037A (en) * | 2007-04-09 | 2007-08-29 | 李水清 | Medicine for treating non-insulin-depending type diabetes |
| CN101708295A (en) * | 2009-12-04 | 2010-05-19 | 卢速江 | Chinese medicinal preparation for treating diabetes and preparation methods thereof |
-
2011
- 2011-10-09 CN CN2011103009875A patent/CN102335249B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1726967A (en) * | 2005-07-26 | 2006-02-01 | 浙江省中药研究所 | Chinese materia medica preparation for treating diabetic nephropathy, and preparation method |
| CN101024037A (en) * | 2007-04-09 | 2007-08-29 | 李水清 | Medicine for treating non-insulin-depending type diabetes |
| CN101708295A (en) * | 2009-12-04 | 2010-05-19 | 卢速江 | Chinese medicinal preparation for treating diabetes and preparation methods thereof |
Non-Patent Citations (4)
| Title |
|---|
| > 20090131 莫娜等 中医药治疗2 型糖尿病胰岛素抵抗用药分析 88-90 1-2 第30卷, 第1期 * |
| > 20090930 喇万英 中医消渴病概述 781-782 1-2 第11卷, 第6期 * |
| 喇万英: "中医消渴病概述", <<华北煤炭医学院学报>> * |
| 莫娜等: "中医药治疗2 型糖尿病胰岛素抵抗用药分析", <<陕西中医>> * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103202423A (en) * | 2013-04-17 | 2013-07-17 | 合肥工业大学 | Fructus trichosanthis polysaccharide composite capsule and preparation method thereof |
| CN104474193A (en) * | 2014-11-17 | 2015-04-01 | 孙静 | Coordinated application of traditional Chinese medicines in diabetes prevention acupuncture therapy |
| CN110755507A (en) * | 2019-10-31 | 2020-02-07 | 贵州省兴仁市中医院 | Formula for treating yin deficiency type diabetes and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102335249B (en) | 2013-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100353983C (en) | Chinese medicine preparation for reducing sugar | |
| CN1742939B (en) | Medicine for treating pulmonary fibrosis and preparing method | |
| CN101596230B (en) | Medicinal composition for treating hepatopathy | |
| CN103301412A (en) | Traditional Chinese medicine composition for treating alcoholic liver | |
| CN101002906A (en) | Compounding traditional Chinese medicine, and its use | |
| CN105920514A (en) | Traditional Chinese medicinal composition for treating metabolic syndrome | |
| CN102526498B (en) | Chinese medicine for eliminating toxic and side effects after nasopharyngeal carcinoma radiotherapy and preparation method and administration way thereof | |
| CN102512615A (en) | Traditional Chinese medicinal composition used for cancer recovery stage | |
| CN104815166B (en) | A kind of Chinese medicine composition for treating diabetes and its preparation and application | |
| CN102145120B (en) | Traditional Chinese medicine composition suitable for treating Type II diabetes | |
| CN102335249B (en) | Oral capsule for treating II-type diabetes | |
| CN104083640B (en) | Traditional Chinese medicinal composition for treating diabetes mellitus and preparation method thereof | |
| CN104107348A (en) | Chinese herbal medicine for blood sugar reducing, and administration method thereof | |
| CN106138608A (en) | A kind of treat the Chinese medicine composition of diabetes, preparation and preparation method thereof | |
| CN105796845A (en) | Application of medicine composition in preparing medicine for treating female climacteric syndromes | |
| CN102526484B (en) | Medicinal composition for decreasing blood sugar | |
| CN104083728A (en) | Processing method of anticancer and tumor eliminating concentrated pill | |
| CN104127663A (en) | Chinese patent medicine used for treating yin-deficiency-caused-fire-excess type insomnia during menstruation | |
| CN104042956A (en) | Medicament for treating diabetes and preparation method thereof | |
| CN101024037A (en) | Medicine for treating non-insulin-depending type diabetes | |
| CN102008634A (en) | Chinese medicinal health-care tea for preventing and treating diabetes | |
| CN101757423B (en) | Traditional Chinese medicine composition for treating myocarditis and preparation method thereof | |
| CN100509019C (en) | Application of Baji capsule in preparing immune enhancement medicament | |
| CN103223107A (en) | Traditional Chinese medicine used for adjusting blood fat and blood pressure, and preparation technology thereof | |
| CN102526425B (en) | Traditional Chinese medicine composition for treating diabetes, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130403 Termination date: 20131009 |